<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01321034</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT 2010-022258-17</org_study_id>
    <nct_id>NCT01321034</nct_id>
  </id_info>
  <brief_title>Effect of Niacin in the Lipoprotein (a) Concentration</brief_title>
  <official_title>Effect of Niacin in the Lipoprotein (a) Concentration With Regard to Apolipoprotein (a) Size and Baseline Lipoprotein (a) Concentration.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Aragones de Ciencias de la Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Miguel Servet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Aragones de Ciencias de la Salud</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives.

        -  To evaluate the absolute and relative Lp(a) lowering effect of 1g/20 mg and 2 g/40 mg
           day of Niacin/Laropiprant in subjects with normal Lp(a) (&lt; 30 mg/dL), high Lp(a) (30-60
           mg/dL) and very high Lp(a) (&gt; 60 mg/dL).

        -  To evaluate the absolute and relative Lp(a) lowering effect of 1g/20 mg and 2 g/40 mg
           day of Niacin/Laropiprant depending on the number of kringle IV-2 repeated copies on the
           apo(a) gene. 2.1.1 Hypotheses.

        -  The Lp(a) lowering effect of niacin is dependent of the pre-treatment Lp(a)
           concentration, with higher absolute and relative reduction in Lp(a) in subjects with
           hyperlipoproteinemia(a).

        -  Lp(a) size, throughout modifying hepatic synthesis of apo(a), is a major factor related
           to the lowering effect variability of niacin in human.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open-label 12-week study, 1g/20 mg day of Niacin/Laropiprant for 4-weeks followed by 8
      additional weeks of 2 g/40 mg day. Subjects with normal Lp(a) will be use as comparative
      group for the other two groups, so no placebo group is required is this study.

      Subjects: volunteers from the Lipid Clinic of Hospital Universitario Miguel Servet of
      Zaragoza, Spain. Subjects were selected according to their previously determined
      Lp(a)concentration. All volunteers before any study procedure will have to give written
      inform consent to a protocol previously approved for the Ethical Committees of our
      institutions.

      Biochemical determinations: lipids: total cholesterol and triglycerides; lipoproteins:
      HDL-cholesterol, Lp(a); apolipoproteins: Apo A1 and apo B and safety biochemical parameters
      (glucose, uric acid, creatinine, liver and muscle enzymes will be measured at baseline and at
      the end of the two treatment periods (weeks 4 and 8).

      An adverse experience questionnaire will be done in each visit. Genetic analysis: apo(a)
      genetic polymorphism responsible of the Lp(a) size variability will be analyzed by a
      PCR-based methodology (Lanktree et al. J Lipid Res 2009; 50: 768-72 ).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>absolute and relative Lp(a) lowering effect of 1g/20 mg and 2 g/40 mg day of Niacin/Laropiprant in subjects with normal Lp(a) (&lt;30 mg/dL), high Lp(a) (30-60 mg/dL) and very high Lp(a) (&gt;60 mg/dL g/40 mg day of Niacin/Laropiprant</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>absolute and relative Lp(a) lowering effect of 1g/20 mg and 2 g/40 mg day of Niacin/Laropiprant depending on the number of kringle IV-2 repeated copies on the apo(a) gene.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Niacin/Laropiprant</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects with normal Lp(a) will be use as comparative group for the other two groups, so no placebo group is required is this study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niacin/Laropiprant</intervention_name>
    <description>1g/20 mg day of Niacin/Laropiprant for 4-weeks followed by 8 additional weeks of 2 g/40 mg day.</description>
    <arm_group_label>Niacin/Laropiprant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt;18 and &lt; 80 years

          2. LDL cholesterol between 70 and 190 mg/dL

          3. Triglycerides &lt; 500 mg/dL

          4. At least 2 Lp(a) determinations previous to the beginning of the study without
             differences &gt;20% or &gt; 20 mg/dL.

          5. No lipid lowering therapy or on stable doses in the last 3 months

        Exclusion Criteria:

          1. Liver disease or liver enzymes &gt;2 times higher than reference values

          2. Creatinine &gt; 2 mg/dL

          3. Active peptic ulcer

          4. Clinical gout in the last year

          5. Uncontrolled diabetes (HbA1c &gt;8%)

          6. Enrolment in other drug clinical trial in the previous 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernando Civeira, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Miguel Servet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital San Jorge</name>
      <address>
        <city>Huesca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Royo Villanova</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2011</study_first_submitted>
  <study_first_submitted_qc>March 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2011</study_first_posted>
  <last_update_submitted>January 8, 2013</last_update_submitted>
  <last_update_submitted_qc>January 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Aragones de Ciencias de la Salud</investigator_affiliation>
    <investigator_full_name>Fernando Civeira</investigator_full_name>
    <investigator_title>Chief Lipid Clinic. Hospital Universitario Miguel Servet de Zaragoza, Spain</investigator_title>
  </responsible_party>
  <keyword>Lipoprotein (a)</keyword>
  <keyword>LPA</keyword>
  <keyword>Niacin</keyword>
  <keyword>Kringle IV-2 repeats</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

